Wegovy maker Novo Nordisk to slash thousands of jobs

Novo Nordisk, the pharmaceutical giant behind Wegovy, announced it will cut 9,000 jobs, representing 11.5% of its workforce and the largest layoff in Denmark's history, aiming to save DKK 8 billion ($1.25bn) annually. This significant restructuring follows a sharp decline in market capitalization from $650bn to $181bn and three profit warnings this year, driven by intense competition from Eli Lilly's Zepbound and sluggish sales in a misjudged obesity market. The new CEO's initial strategic move seeks to simplify the company's structure, reignite investor confidence, and redirect resources towards R&D and manufacturing to bolster future growth.

Analysis

Novo Nordisk is undertaking a significant corporate restructuring, cutting 9,000 jobs, or 11.5% of its workforce, in a bid to save 8 billion Danish crowns ($1.25bn) annually. This drastic measure, the largest layoff in Denmark's history, is a direct response to severe financial headwinds and competitive pressures. The company's market capitalization has collapsed from a peak of $650bn to $181bn, accompanied by a nearly 46% year-to-date stock decline and three profit warnings this year. The core challenge stems from intensified competition in the weight-loss drug market from Eli Lilly, whose Zepbound product has overtaken Novo's Wegovy in weekly US prescriptions. This restructuring represents the first major strategic action by new CEO Maziar Mike Doustdar to simplify the organization, which was criticized for expanding complexity too quickly and misjudging the consumer-driven nature of the obesity market. The company plans to redirect savings, including an expected one billion DKK in Q4, towards R&D, manufacturing expansion, and market access to bolster its competitive stance and support future product launches, such as a pill version of Wegovy.

Key Decisions for Investors

• Investors should monitor Novo Nordisk's upcoming Q3 results for evidence that this major restructuring can stabilize sales and margins, as another profit warning remains a significant risk highlighted by analysts.
• The pronounced divergence between Novo Nordisk's decline and Eli Lilly's ascendancy suggests investors should re-evaluate their exposure to the GLP-1 market, as Lilly is currently demonstrating superior competitive momentum.
• Long-term recovery for Novo is now contingent on the new CEO's ability to effectively reinvest the projected $1.25bn in annual savings into the R&D pipeline and manufacturing to counter market share losses in the crucial US market.